Bayer AG based in Germany has suspended the sale of its anti-bleeding drug Trasylol. This action came about at the request of U.S. health officials pending further information based on a Canadian study. This study suggests it’s linked to a 50 percent higher risk of death when used in coronary by-pass surgery.
Approved in 1993, the drug has been under a cloud for more than a year amid data suggesting it might boost the risk of death, serious kidney damage and stroke. Bayer had estimated that sales of the injection drug were roughly $91 million in the U.S. alone.
Money could be the issue involved when it was learned that the studies that link Trasylol to increased risk of death was previously withheld by Bayer from the FDA due to what the company called “regrettable human error”.
The actual number of deaths that can attributed to the use of Trasylol is still not available. The frightening aspect of this drug snafu is that the patient would never know they were receiving the deadly drug because it is administered during surgery when the patient can’t question the use of drugs being used on their body even if they wanted to ask about risks.
Most patients assume their doctor will only use drugs safe and effective on them, both during surgery, and afterward during recovery. If you have questions about drugs used on you or your loved ones during any heart related surgery or procedure, and feel you may need the services of a compassionate and caring law firm, contact us here at Bailey and Oliver Law Firm.
For more information on this subject, please refer to the section on Drugs, Medical Devices and Implants.